Market Context — Why This Technology, Why Now

The escalating prevalence of chronic fibrotic diseases globally, driven by aging demographics and lifestyle factors, creates immense pressure on healthcare systems to find more effective, disease-modifying treatments. Current therapeutic options are often palliative, leading to high long-term costs and poor patient outcomes. This unmet medical need, coupled with increasing R&D investment in regenerative medicine and targeted therapies, positions novel approaches like myofibroblast deactivation as critical for future market leadership and patient care improvement.

Key Competitive Advantages
01

Enables fundamental treatment for fibrotic diseases by directly suppressing myofibroblast activation, aiming for dramatic improvement over symptomatic therapies.

02

Offers broad applicability across various fibrotic diseases, targeting a common mechanism in organs such as the heart, lungs, liver, and kidneys.

03

Overcomes limitations of existing treatments by enabling precise cellular-level control, differentiating it as a novel therapeutic modality.

Market Opportunity
🫀 Cardiovascular Disease Therapeutics
$800M–$13.5B globally (AI est.)
Myocardial fibrosis is a major cause of heart failure, with patient numbers increasing due to aging populations. Existing treatments cannot fully halt progression, creating high demand for fundamental therapies in this market.
Large pharmaceutical companies focused on cardiology Biotech firms developing heart failure treatments Medical device companies exploring combination therapies
🫁 Respiratory Disease Therapeutics
$350M–$5.5B globally (AI est.)
Effective treatments for highly fatal fibrotic lung diseases, such as idiopathic pulmonary fibrosis, are limited. There is an urgent need for new therapeutic modalities in this growing market.
Specialty pharma companies in pulmonology Biotech startups focused on rare lung diseases Contract research organizations for respiratory drug development
🧪 Renal and Hepatic Disease Therapeutics
$450M–$10B globally (AI est.)
Fibrosis is deeply involved in the progression of chronic kidney disease and liver cirrhosis, often leading to dialysis or transplantation in advanced stages. Demand for fundamental therapies that allow for early intervention is extremely high, driving significant market expansion.
Pharmaceutical companies with nephrology/hepatology portfolios Biotech firms developing anti-fibrotic agents Academic research institutions seeking drug candidates
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a partial peptide of Tcf21 protein capable of deactivating myofibroblasts, specifically covering amino acid sequences of 25-30 residues that form a complex with Tcf3 protein. With 15 claims, it offers broad technical coverage and strong defensive capabilities, having successfully navigated rigorous examination against six prior art documents.

Competitive White Space

This patent primarily covers the specific peptide and its function. White space exists in developing novel drug delivery systems for the peptide, exploring combination therapies with existing anti-fibrotic agents, or identifying new diagnostic biomarkers beyond Tcf21/Tcf3 complex activity.

Economic Impact
~$200M/year estimated market creation potential (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Fibrotic diseases, including heart failure, idiopathic pulmonary fibrosis, and liver cirrhosis, each represent substantial drug markets. For instance, the domestic market for idiopathic pulmonary fibrosis treatments alone is valued at several hundred million USD (AI est.). If a new therapeutic drug based on this technology captures approximately 5% to 10% of these fibrotic disease markets, it could generate an economic impact of ~$200M annually (AI est.).

Speed to Market
3× faster than in-house development
This technology benefits from established myofibroblast deactivation mechanisms and identified functional peptide sequences, validated through in vitro efficacy studies at a university research institution. Licensees can significantly shorten the basic research phase, accelerating entry into preclinical and clinical development. This could reduce time to market by approximately 7 years compared to de novo in-house development.
Competitive Positioning

X: Contribution to Fundamental Treatment
Y: Breadth of Disease Applicability

Business Models & Applications
💊 Novel Peptide Drug Development
Develop innovative peptide drugs based on this technology, aiming to deactivate myofibroblasts. The goal is to launch these as fundamental therapies for fibrotic diseases.
🔬 Diagnostic & Biomarker Provision
Potentially contribute to developing early diagnostic biomarkers for fibrotic diseases, or tools to monitor treatment efficacy, using Tcf21/Tcf3 complex activity as an indicator.
🧬 Application in Regenerative Medicine
As a technology to suppress organ fibrosis, it is expected to be applied in regenerative medicine for optimizing tissue repair processes or functionalizing cell scaffold materials.
Adjacent Application Opportunities
🔬 Research Reagents & Tools
High-Functionality Fibrosis Research Kits
This technology could be offered as cell culture kits or in vitro assay reagents incorporating Tcf21/Tcf3 peptides, potentially becoming a standard tool for fibrosis mechanism research. It could significantly enhance research efficiency, accelerating discovery by an estimated 20-30%.
🧴 Cosmetics & Beauty
Anti-Aging Skin Fibrosis Improvement
Skin fibrosis is a primary cause of wrinkles and sagging. Developing functional cosmetics or serums incorporating peptides based on this technology could offer new value in the anti-aging market, potentially reducing visible signs of aging by 15-25%.
🐾 Veterinary Medicine
Pet Fibrosis Treatment Solutions
Fibrotic diseases associated with heart and kidney conditions are common in pets like dogs and cats, yet effective treatment options are limited. Applying this technology to develop veterinary pharmaceuticals could improve pet quality of life by an estimated 30-50% in affected animals.
Integration Roadmap — Estimated 51-Month Deployment
Phase 1: Basic Validation & Preclinical Research
Duration: 9 months
Conduct additional in vitro/in vivo evaluations of the Tcf21 partial peptide's efficacy and safety within the licensee's research infrastructure, confirming consistency with existing data.
Phase 2: Clinical Development Preparation & Optimization
Duration: 15 months
Advance formulation studies, optimize administration routes, and conduct toxicity tests for the peptide. Concurrently, prepare regulatory submissions and initiate clinical trial protocol development.
Phase 3: Clinical Trial Initiation & Commercialization
Duration: 27 months
Initiate Phase I clinical trials to assess human safety and pharmacokinetics. Simultaneously, develop concrete business strategies for future production systems and market launch.
Technical Feasibility
This technology clearly defines a specific partial peptide and its functional mechanism, with in vitro deactivation confirmed. Licensees with peptide synthesis capabilities and cell culture assay systems can relatively easily proceed with technical validation. Classified under IPC A61K38/17 (Peptide Drugs), it possesses a technological foundation that facilitates integration into existing pharmaceutical development processes.
Success Scenario
Adopting this technology could enable licensees to develop novel drugs aimed at fundamentally improving disease states, a challenge for existing therapies. This has the potential to significantly enhance the quality of life for patients suffering from intractable diseases, contributing socially while creating new medical markets. In the future, it is estimated to potentially replace existing drug markets, contributing hundreds of millions of USD in annual sales (AI est.).
Patent Record
APPLICATION NO.
特願2021-078161
REGISTRATION NO.
7723955
FILING DATE
2021/04/30
GRANT DATE
2025/08/06
EXPIRATION DATE
2041/04/30
PATENT HOLDER
学校法人東海大学
Examination History
2024年04月22日
出願審査請求書
2025年04月22日
拒絶理由通知書
2025年06月18日
意見書
2025年06月18日
手続補正書（自発・内容）
2025年07月08日
特許査定